S1PR2 and pulmonary fibrosis: Inhibition of S1PR2 with antagonists mitigated bleomycin-induced pulmonary fibrosis, reducing collagen deposition, inflammatory cell recruitment, and expression of pro-inflammatory mediators, including IL-4, IL-5, IFN-Y, and TNF-α [26,122].